Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

Bibliographic Details
Main Authors:	Sattar, N, Valensi, P, Preiss, D, Dent, R, Bridges, I, Ruzza, A, Cyrille, M, Handelsman, Y
Format:	Conference item
Published:	Springer Verlag 2016

Similar Items

Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies
by: Toth, P, et al.
Published: (2017)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
by: Preiss, D, et al.
Published: (2016)

Effect of evolocumab on lipoprotein particles
by: Toth, PP, et al.
Published: (2017)

Osler and neurology.
by: Ebers, G
Published: (1985)

IN DEFENSE OF OSLER
by: Ebers, G, et al.
Published: (1982)

OSLER AND NEUROLOGY
by: Ebers, G
Published: (1982)

In defence of Osler.
by: Ebers, G, et al.
Published: (1982)

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
by: Sattar, N, et al.
Published: (2016)

Effect of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab on glycemia, body weight, and new-onset diabetes mellitus
by: Sattar, N, et al.
Published: (2017)

Pursuit of Osler's sign
by: Suriya Djeamourthy, et al.
Published: (2021-01-01)

Osler′s sign revisited
by: Annapurna Kumar, et al.
Published: (2015-01-01)

Osler Centenary Papers: Management of pleural infection: Osler’s final illness and recent advances
by: Gregory, P, et al.
Published: (2019)

William Osler (1849-1919).
by: Ebers, G
Published: (2006)

Can the OSLER MWT be improved?
by: Turnbull, C, et al.
Published: (2015)

Osler’s nodes in infective endocarditis
by: Rolando A. Zamora Gonzalez, et al.
Published: (2023-01-01)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01)

Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01)

Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial
by: Preiss, D, et al.
Published: (2016)

Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)
by: Marian Goicoechea, et al.
Published: (2022-05-01)

Adherence to deferoxamine therapy: Heeding hippocrates and osler
by: Watkins, F, et al.
Published: (2004)

Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study
by: Isabella Sudano, et al.
Published: (2024-01-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
by: Preiss, D, et al.
Published: (2016)

South Asia today: William Osler's world with antibiotics
by: Basnyat, B
Published: (2018)

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.
by: Laura E Korthauer, et al.
Published: (2022-01-01)

RENDU-OSLER-WEBER DISEASE AT 75 YEARS OLD WOMAN
by: A. S. Barmenova, et al.
Published: (2017-08-01)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
by: Zhenxian Li, et al.
Published: (2023-05-01)

Lipid lowering effects and safety of evolocumab in Chinese patients at very high cardiovascular risk: a single-center study
by: Meng Chai, et al.
Published: (2023-06-01)

Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study
by: Ju Chen, et al.
Published: (2023-01-01)

Malformações arteriovenosas pulmonares na síndrome de Rendu-Osler-Weber
by: Cristiane Ferreira de Araújo-Gomes, et al.
Published: (2024-04-01)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
by: Syed Raza Shah, et al.
Published: (2017-07-01)

Rendu-Osler-Weber Disease with High Pulmonary Hypertension and Interstitial Lung Disease
by: Yu. A. Lutokhina, et al.
Published: (2023-05-01)

A Rare Case of Upper Gastrointestinal Bleeding: Osler-Weber-Rendu Syndrome
by: Anna Jargielo, et al.
Published: (2022-02-01)

Hereditary Hemorrhagic Telangiectasia: Success of the Osler Calendar for Documentation of Treatment and Course of Disease
by: Caroline T. Seebauer, et al.
Published: (2021-10-01)

OSLER – WEBER – RENDU SYNDROME: A RARE CASE OF UPPER GASTROINTESTINAL BLEEDING
by: Farrukh Sher, et al.
Published: (2022-06-01)

An interfaith dialogue with Sir William Osler: crossing the divide of COVID-19 pandemic
by: Jonathan Kopel, et al.
Published: (2020-09-01)

Congestive cirrhosis in Osler-Weber-Rendu syndrome: A rare case report
by: Patrícia Leitão, PhD, et al.
Published: (2018-02-01)

Human Rights and Schooling: An ethical framework for teaching for social justice, by Audrey Osler
by: Judith L. Pace
Published: (2017-06-01)

Síndrome de Rendu-Osler-Weber: presentación de un caso clínico
by: Freyli Bustamante, et al.
Published: (2016-08-01)

Getting CLOSLER ("Closer to Osler"): Developing an Online Community Focused on Clinical Excellence
by: Charlie Stube, et al.
Published: (2019-03-01)

EXPERIENCE WITH THE USE OF EVOLOCUMAB THERAPY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (IN KARELIA REPUBLIC)
by: V. A. Korneva, et al.
Published: (2020-06-01)